Welcome to our dedicated page for PETVIVO HOLDINGS news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS stock.
PetVivo Holdings Inc (PETV) is an emerging biomedical device company with a focus on licensing and commercializing innovative medical devices for pets, known as pet therapeutics. The company aims to capitalize on investments in the human biomaterials and medical device industries to bring therapeutics to pets efficiently. As part of its strategy, PetVivo in-licenses proprietary products from human medical device companies for pet use. Its wholly-owned subsidiaries include PetVivo, Inc., Gel-Del Technologies, Inc., and CosmetaLife Corporation.
Rhea-AI Summary
PetVivo Holdings, Inc. announces its participation in the ACVSMR Symposium to showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, aimed at managing joint pain in pets. The event will be held from April 11th to April 13th, 2024, in Naples, Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. appoints Garry Lowenthal as the new Chief Financial Officer, bringing over 25 years of extensive experience in finance management and operations. Mr. Lowenthal's background includes leading equity capital raising transactions for private and public companies, serving on the national board of Financial Executives International, and working for top CPA/Consulting firms like PricewaterhouseCoopers and Deloitte.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. dual lists on Upstream's global securities trading app, providing digital-first investors worldwide with streamlined access to PETV shares. The company's free NFT commemorating the listing is available for all Upstream participants. Non-U.S. investors can deposit or trade PETV securities on Upstream, with trading starting after the first offer is placed. The market operates 5 days a week, 20 hours a day, offering real-time trading and settlement with transparent orderbooks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. announced the successful completion of the first cohort of dogs in a clinical study focusing on the benefits of an intra-articular injection of collagen-elastin hydrogel microparticles for dogs with osteoarthritis. The study showed promising results with significant improvements in CBPI scores, hip extension, visual lameness scores, and quality of life assessments. Spryng™ with OsteoCushion™ Technology appears to be a viable option for managing coxofemoral joint osteoarthritis in companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV) to dual list shares on Upstream for global trading starting March 5, 2024. Shareholders to receive commemorative NFT. Upstream offers real-time trading, transparent orderbook, and digital collectibles for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. will showcase its innovative veterinary medical device, SPRYNG™ with OsteoCushion™ Technology, at the Western Veterinary Conference. The conference, hosting over 15,000 participants, offers a platform for PetVivo to engage with industry professionals and promote its joint pain management solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. (Nasdaq: PETV) announces financial results for the third quarter of 2024, highlighting a multi-distribution sales strategy and the addition of a new Board member. The company raised $1.2 million in a private offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. announced the release of the results of a clinical study conducted by Inotiv, Inc., which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (Spryng™ with OsteoCushion™ Technology) into the joints of cats. The study demonstrated the excellent safety profile of Spryng when injected into 40 joints across 10 individual cats, showing similar results to a benign control in terms of incidences of lameness, joint swelling, or pain after injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. will report financial results on February 12, 2024, after market close. The company is focused on commercializing innovative medical therapeutics for animals. A conference call to discuss the results will be held at 4:00 p.m. CT (5:00 p.m. ET) on the same day. The webcast and earnings release materials can be accessed on PetVivo’s Investor Relations website. PetVivo uses its Investor Relations website to disclose material nonpublic information and comply with its disclosure obligations under Regulation FD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. announces the results of a clinical study examining the safety of intra-articular injections of a collagen-elastin hydrogel microparticulate biomaterial into the joints of dogs. The study demonstrated the safety profile of the veterinary medical device, Spryng with OsteoCushion Technology, in managing joint-related afflictions in companion animals. The data provided from the study indicates that the use of Spryng was similar to a benign control in regard to incidences of lameness, joint swelling, or pain after injection, with post-injection outcomes often no different than pre-injection baseline measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
FAQ
What is the current stock price of PETVIVO HOLDINGS (PETV)?
The current stock price of PETVIVO HOLDINGS (PETV) is $0.57 as of December 24, 2024.
What is the market cap of PETVIVO HOLDINGS (PETV)?
The market cap of PETVIVO HOLDINGS (PETV) is approximately 9.2M.
What is PetVivo Holdings Inc's focus?
PetVivo Holdings Inc focuses on licensing and commercializing innovative medical devices for pets, known as pet therapeutics.
How does PetVivo leverage investments in other industries?
PetVivo leverages investments in the human biomaterials and medical device industries to efficiently bring therapeutics to pets.
What is PetVivo's strategy regarding proprietary products?
PetVivo in-licenses proprietary products from human medical device companies specifically for use in pets.
What are the wholly-owned subsidiaries of PetVivo Holdings Inc?
PetVivo Holdings Inc's wholly-owned subsidiaries include PetVivo, Inc., Gel-Del Technologies, Inc., and CosmetaLife Corporation.
What is the goal of PetVivo Holdings Inc?
The goal of PetVivo Holdings Inc is to commercialize therapeutics for pets in a capital and time-efficient manner.
What industry does PetVivo Holdings Inc operate in?
PetVivo Holdings Inc operates in the biomedical device industry with a focus on pet therapeutics.
How does PetVivo Holdings Inc differentiate itself in the market?
PetVivo Holdings Inc differentiates itself by focusing on innovative medical devices for pets and leveraging investments in related industries.
Where is PetVivo Holdings Inc headquartered?
PetVivo Holdings Inc is headquartered in the United States.
What is the relationship between PetVivo Holdings Inc and Gel-Del Technologies, Inc?
Gel-Del Technologies, Inc is a wholly-owned subsidiary of PetVivo Holdings Inc.
What is the significance of CosmetaLife Corporation to PetVivo Holdings Inc?
CosmetaLife Corporation is a wholly-owned subsidiary of PetVivo Holdings Inc, playing a role in the company's operations.
PETVIVO HOLDINGS INC